LEXINGTON, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to treat disease and improve human health, today announced a research collaboration with researcher

LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will

KB109 demonstrated favorable safety and tolerability profile Kaleido intends to file an Investigational New Drug (IND) application, with the goal of advancing KB109 directly into a pivotal registration program Company to host conference call today at 8:30am ET LEXINGTON, Mass., March 24, 2021

Topline data from two ongoing COVID-19 studies with KB109 expected in Q1 2021 KB295 study in patients with ulcerative colitis remains on track with topline data anticipated mid-year 2021 LEXINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc.

LEXINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Dan Menichella, President

LEXINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that, in connection with its

LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced the pricing of an underwritten

LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that it intends to sell, subject

LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” conference this afternoon at

Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities Topline data from full study population of 350 patients and results of second study of KB109 are expected in the first